WO2019177374A8 - 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 - Google Patents

2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2019177374A8
WO2019177374A8 PCT/KR2019/002914 KR2019002914W WO2019177374A8 WO 2019177374 A8 WO2019177374 A8 WO 2019177374A8 KR 2019002914 W KR2019002914 W KR 2019002914W WO 2019177374 A8 WO2019177374 A8 WO 2019177374A8
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
inflammatory disease
prevention
pharmaceutical composition
Prior art date
Application number
PCT/KR2019/002914
Other languages
English (en)
French (fr)
Other versions
WO2019177374A1 (ko
Inventor
정명호
김주빈
전현호
이윤호
이화
강세인
조서현
강주희
김환
김현경
서경아
손정범
김남두
석지윤
이선화
Original Assignee
보로노이바이오 주식회사
보로노이 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보로노이바이오 주식회사, 보로노이 주식회사 filed Critical 보로노이바이오 주식회사
Publication of WO2019177374A1 publication Critical patent/WO2019177374A1/ko
Publication of WO2019177374A8 publication Critical patent/WO2019177374A8/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 상기 화합물은 EGFR(epidermal growth factor receptor) 야생형 또는 돌연변이에 대하여 높은 억제능을 나타내고, JAK3에 대한 억제효과가 우수하므로, EGFR 야생형 또는 EGFR 돌연변이가 발현된 암이나, JAK3의 활성과 관련된 암 또는 염증질환의 치료에 유용하게 사용될 수 있고, 폐암 세포주 증식 억제능이 우수한 바, 특히, 폐암의 치료에 유용하게 사용될 수 있다.
PCT/KR2019/002914 2018-03-13 2019-03-13 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 WO2019177374A1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20180029416 2018-03-13
KR10-2018-0029416 2018-03-13
KR20180070252 2018-06-19
KR10-2018-0070252 2018-06-19

Publications (2)

Publication Number Publication Date
WO2019177374A1 WO2019177374A1 (ko) 2019-09-19
WO2019177374A8 true WO2019177374A8 (ko) 2020-06-18

Family

ID=67906811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/002914 WO2019177374A1 (ko) 2018-03-13 2019-03-13 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물

Country Status (2)

Country Link
KR (1) KR20190108080A (ko)
WO (1) WO2019177374A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622966B2 (en) 2018-05-25 2023-04-11 A2A Pharmaceuticals, Inc. Highly potent TACC3 inhibitor as a novel anticancer drug candidate
CN115838369A (zh) 2019-03-19 2023-03-24 株式会社沃若诺伊 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
US20240051945A1 (en) * 2020-10-30 2024-02-15 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof
JP2024518711A (ja) * 2021-04-12 2024-05-02 エーツーエー ファーマシューティカルズ インコーポレーテッド 癌を処置するための組成物及び方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
WO2008092199A1 (en) * 2007-01-31 2008-08-07 Cytopia Research Pty Ltd Thiopyrimidine-based compounds and uses thereof
KR20110025224A (ko) * 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
CN103501612B (zh) * 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
US10017477B2 (en) * 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2017059280A1 (en) * 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors

Also Published As

Publication number Publication date
KR20190108080A (ko) 2019-09-23
WO2019177374A1 (ko) 2019-09-19

Similar Documents

Publication Publication Date Title
WO2019177374A8 (ko) 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
WO2019177375A8 (ko) 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
PH12021551529A1 (en) 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
CR20200614A (es) Compuestos heterocíclicos como inmunomoduladores
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
WO2018155916A3 (ko) 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
MX2017004234A (es) Inhibidor del egfr y preparacion y aplicacion del mismo.
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
IN2014MN02497A (ko)
EP3693369A3 (en) Bromodomain inhibitors
CN106687454B8 (zh) 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途
AU2011269989A8 (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
MY149960A (en) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
GEP20227344B (en) Pyrimidine compound as jak kinase inhibitor
AU2018381574A1 (en) Pyrrolo(pyrazolo)pyrimidine derivative as LRRK2 inhibitor
PH12021551268A1 (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
WO2016126085A3 (ko) 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
UA83314C2 (ru) 2-(пиридин-2-ил)пиримидиновые соединения и их применение для борьбы с вредными грибами
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
CR20220537A (es) [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2
MX2021008667A (es) Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo.
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
EP3980046A4 (en) KRAS G12V MUTANT THAT BINDS TO JAK1, INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19767796

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19767796

Country of ref document: EP

Kind code of ref document: A1